Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The benzodiazepine binding site is a specific allosteric modulatory site located on the gamma-aminobutyric acid type A (GABAA) receptor, a major inhibitory neurotransmitter receptor in the mammalian central nervous system. It is found in the extracellular domain at the interface between an α (typically α1) and γ (typically γ2) subunit. Benzodiazepines bind to this site to enhance GABA-induced chloride ion flux through the channel, leading to neuronal hyperpolarization. This underlies their anxiolytic, anticonvulsant, muscle-relaxant, sedative-hypnotic properties. Other ligands can act as negative allosteric modulators or antagonists at this same site.
Positive allosteric modulation of GABAA receptor activity, increasing chloride ion flux and hyperpolarizing neurons.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Benzodiazepine Binding Site on Gamma-Aminobutyric Acid Type A Receptor.